[go: up one dir, main page]

EE04661B1 - Viirus-indutseeritud ssteemse šoki ja hingamispuudulikkuse reverseerimine lmfotoksiin-beeta raja blokeerimise abil - Google Patents

Viirus-indutseeritud ssteemse šoki ja hingamispuudulikkuse reverseerimine lmfotoksiin-beeta raja blokeerimise abil

Info

Publication number
EE04661B1
EE04661B1 EEP200100211A EEP200100211A EE04661B1 EE 04661 B1 EE04661 B1 EE 04661B1 EE P200100211 A EEP200100211 A EE P200100211A EE P200100211 A EEP200100211 A EE P200100211A EE 04661 B1 EE04661 B1 EE 04661B1
Authority
EE
Estonia
Prior art keywords
induced
blocking
lmphotoxin
reversal
virus
Prior art date
Application number
EEP200100211A
Other languages
English (en)
Inventor
L. Browning Jeffrey
Puglielli Maryann
Ahmed Rafi
Original Assignee
Biogen, Incorporated
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated, Emory University filed Critical Biogen, Incorporated
Publication of EE200100211A publication Critical patent/EE200100211A/et
Publication of EE04661B1 publication Critical patent/EE04661B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EEP200100211A 1998-10-09 1999-10-08 Viirus-indutseeritud ssteemse šoki ja hingamispuudulikkuse reverseerimine lmfotoksiin-beeta raja blokeerimise abil EE04661B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09
PCT/US1999/023477 WO2000021558A1 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Publications (2)

Publication Number Publication Date
EE200100211A EE200100211A (et) 2002-08-15
EE04661B1 true EE04661B1 (et) 2006-08-15

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100211A EE04661B1 (et) 1998-10-09 1999-10-08 Viirus-indutseeritud ssteemse šoki ja hingamispuudulikkuse reverseerimine lmfotoksiin-beeta raja blokeerimise abil

Country Status (27)

Country Link
US (3) US20020001585A1 (et)
EP (1) EP1119370B1 (et)
JP (2) JP4713738B2 (et)
KR (1) KR100888832B1 (et)
CN (1) CN1200733C (et)
AT (1) ATE329618T1 (et)
AU (1) AU777492C (et)
BR (1) BR9915025A (et)
CA (1) CA2344049C (et)
CY (1) CY1105059T1 (et)
CZ (1) CZ20011272A3 (et)
DE (1) DE69931944T2 (et)
DK (1) DK1119370T3 (et)
EA (1) EA006703B1 (et)
EE (1) EE04661B1 (et)
ES (1) ES2267294T3 (et)
HU (1) HUP0103773A3 (et)
IL (2) IL142284A0 (et)
IS (1) IS2514B (et)
NO (1) NO326905B1 (et)
NZ (1) NZ510560A (et)
PL (1) PL195264B1 (et)
PT (1) PT1119370E (et)
SG (1) SG121778A1 (et)
SK (1) SK4662001A3 (et)
TR (1) TR200100974T2 (et)
WO (1) WO2000021558A1 (et)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
EP1119370B1 (en) * 1998-10-09 2006-06-14 Biogen Idec MA Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
EP1674575B1 (en) * 2000-04-12 2010-10-06 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
EP1756162A1 (en) * 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
SG178002A1 (en) 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
WO2009039310A2 (en) * 2007-09-18 2009-03-26 La Jolla Institute For Allergy And Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ES2157889T3 (es) * 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
US5795964A (en) 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
US7030080B2 (en) 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69334224D1 (de) 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
SK286497B6 (sk) 1995-01-26 2008-11-06 Biogen Idec Ma, Inc. Zmes LT-alfa/beta heteromérneho komplexu a/alebo najmenej jedného LT-beta-R aktivujúceho činidla, farmaceutický prostriedok, LT-beta-R aktivujúce činidlo a spôsob jeho výberu
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
EA002983B1 (ru) * 1996-10-25 2002-12-26 Байоджен, Инк. Способ изменения гуморального иммунного ответа с помощью агентов, блокирующих рецепторы бета-лимфотоксина
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
EP1119370B1 (en) * 1998-10-09 2006-06-14 Biogen Idec MA Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体

Also Published As

Publication number Publication date
IS2514B (is) 2009-06-15
EP1119370A1 (en) 2001-08-01
NZ510560A (en) 2003-09-26
US20020001585A1 (en) 2002-01-03
EE200100211A (et) 2002-08-15
PL347177A1 (en) 2002-03-25
EA006703B1 (ru) 2006-02-24
BR9915025A (pt) 2001-08-14
WO2000021558A9 (en) 2001-05-25
PT1119370E (pt) 2006-09-29
WO2000021558A1 (en) 2000-04-20
KR20010080073A (ko) 2001-08-22
CY1105059T1 (el) 2010-03-03
IS5882A (is) 2001-03-09
DE69931944D1 (de) 2006-07-27
IL142284A (en) 2009-11-18
AU777492B2 (en) 2004-10-21
TR200100974T2 (tr) 2001-11-21
CZ20011272A3 (cs) 2001-09-12
CA2344049A1 (en) 2000-04-20
AU6296499A (en) 2000-05-01
CA2344049C (en) 2009-12-15
DE69931944T2 (de) 2007-02-08
NO20011757L (no) 2001-06-08
SK4662001A3 (en) 2001-11-06
EA200100430A1 (ru) 2001-10-22
HUP0103773A3 (en) 2003-10-28
CN1323223A (zh) 2001-11-21
IL142284A0 (en) 2002-03-10
ATE329618T1 (de) 2006-07-15
DK1119370T3 (da) 2006-10-02
PL195264B1 (pl) 2007-08-31
SG121778A1 (en) 2006-05-26
NO20011757D0 (no) 2001-04-06
EP1119370B1 (en) 2006-06-14
JP2010155852A (ja) 2010-07-15
JP2002527403A (ja) 2002-08-27
US20090087403A1 (en) 2009-04-02
AU777492C (en) 2005-05-26
US7452530B2 (en) 2008-11-18
HUP0103773A2 (hu) 2002-01-28
NO326905B1 (no) 2009-03-16
ES2267294T3 (es) 2007-03-01
US20040198635A1 (en) 2004-10-07
JP4713738B2 (ja) 2011-06-29
KR100888832B1 (ko) 2009-03-17
CN1200733C (zh) 2005-05-11

Similar Documents

Publication Publication Date Title
EE04661B1 (et) Viirus-indutseeritud ssteemse šoki ja hingamispuudulikkuse reverseerimine lmfotoksiin-beeta raja blokeerimise abil
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
EE03523B1 (et) Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
DK0680326T3 (da) Farmaceutisk formulering af nikotinafhængighed.
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
UA41355C2 (uk) Засіб для лікування нейро-сніду
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
MD1716C2 (ro) Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
ES2193285T3 (es) Inhibidor de oxido nitrico (no)-sintasa para prevenir la diabetes de tipo ii.
ATE145135T1 (de) Verwendung von riluzol zum schutz gegen strahlenschäden
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
DK1032407T3 (da) Anvendelse af putamen ovi
ES2166778T3 (es) Factor de crecimiento ii de tipo insulina como agente antitumoral.
DK1007047T3 (da) Anvendelse af mizolastin til fremstilling af et lægemiddel beregnet til inflammationsbehandling
TR199801043T2 (xx) Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler.
MX9701031A (es) Utilizacion de la selegilina para el tratamiento de enfermedades epilepticas.

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20161008